li001

ELI-002 2P is an innovative “off-the-shelf” therapeutic vaccine targeting KRAS mutations, which drive approximately 90% of pancreatic cancers and 50% of colorectal cancers . Unlike personalized mRNA vaccines, this standardized approach delivers synthesized peptides directly to lymph nodes to train T-cells to recognize and attack KRAS-mutated cancer cells. Key Clinical Results: The Phase 1 AMPLIFY-201 trial […]

Zongertinib is a newly approved oral targeted therapy for patients with unresectable or metastatic HER2-mutated non-squamous non-small cell lung cancer (NSCLC) who have received prior treatment. Approved by the FDA in August 2025, it is the first oral option specifically for this patient group, marking a significant advance in targeted lung cancer therapy. Zongertinib works